Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Valeant's Pearson says timing of return uncertain

Published 01/25/2016, 07:48 AM
Updated 01/25/2016, 07:50 AM
© Reuters. J. Michael Pearson, Chairman of the board and Chief Executive Officer of Valeant Pharmaceuticals International Inc., speaks during their annual general meeting in Laval, Quebec

© Reuters. J. Michael Pearson, Chairman of the board and Chief Executive Officer of Valeant Pharmaceuticals International Inc., speaks during their annual general meeting in Laval, Quebec

(Reuters) - Valeant Pharmaceuticals (N:VRX) International Inc's (TO:VRX) ailing chief executive, Michael Pearson (L:PSON), said he was on the road to recovery but was uncertain about when he would return from medical leave.

"I'm glad to say that I'm on the road to recovery and although the timing of my return remains uncertain, I look forward to being back at work when able," Pearson said in a memo to employees.

Pearson, who joined Valeant as CEO in 2010 after a 23-year career at consultancy McKinsey & Co, was hospitalized with severe pneumonia in late December.

Valeant in January named its former chief financial officer and Pearson's long-time lieutenant, Howard Schiller, as interim chief executive.

During most of the years Pearson led the Laval, Quebec-based company, Schiller worked alongside him. The two employed a rapid growth strategy based on a constant stream of acquisitions and drug price increases.

© Reuters. J. Michael Pearson, Chairman of the board and Chief Executive Officer of Valeant Pharmaceuticals International Inc., speaks during their annual general meeting in Laval, Quebec

But last year Valeant's surging growth stalled amid questions about its pricing, accounting practices, and for close ties to a specialty pharmacy.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.